Response letter: “Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules”

Figures & data

Table 1. Percentage of subjects with TBE NT ≥10 at d 300 (visit 8) – PP set.

Age group (years)	TBE_R, N (%)	TBE_C, N (%)	TBE_AC, N (%)
12–17	13 (100)	10 (71)	19 (86)
18–49	27 (75)	25 (74)	36 (51)
≥50	7 (50)	7 (64)	10 (56)
≥60	1 (33)	1 (100)	2 (50)

TBE, tick-borne encephalitis; N (%), number (percentage) of subjects; NT, neutralizing titer; PP, per-protocol; TBE_R, TBE_C and TBE_AC, rapid, conventional and accelerated conventional TBE vaccination schedules in the V48P7 study.

Table 2. GMTs at d 300 (visit 8) – PP set.

	GMT (95% CI)
Age group (years)	TBE_R	TBE_C	TBE_AC
12–17	47 (25–86)	35 (20–63)	33 (21–52)
18–49	18 (13–25)	21 (15–29)	12 (9–15)
≥50	13 (7–24)	13 (7–26)	11 (6–19)
≥60	14 (6–33)	32 (7–141)	9 (4–18)

GMT, geometric mean titer; TBE, tick-borne encephalitis; PP, per-protocol; TBE_R, TBE_C and TBE_AC, rapid, conventional and accelerated conventional TBE vaccination schedules in the V48P7 study.

Table 3. GMTs per visit and age group – PP set.

			TBE_R		TBE_C		TBE_AC
Age group (years)	Visit	N	GMT (95% CI)	N	GMT (95% CI)	N	GMT (95% CI)
15–49	P.b. V48P7E1	35	638 (413–984)	39	1299 (861–1959)	80	1008 (757–1343)
	Visit 18 (Y 6)	32	456 (278–747)	39	341 (218–533)	77	295 (215–406)
	Visit 19 (Y 7)	31	477 (300–760)	39	384 (254–582)	76	359 (267–483)
	Visit 20 (Y 8)	31	289 (180–464)	38	252 (164–386)	75	239 (177–325)
	Visit 21 (Y 9)	31	436 (270–704)	36	330 (211–514)	74	314 (231–429)
	Visit 22 (Y 10)	31	369 (217–628)	37	359 (221–585)	75	306 (217–430)
≥50	P.b. V48P7E1	13	201 (111–364)	12	733 (395–1361)	25	914 (595–1403)
	Visit 18 (Y 6)	13	207 (107–401)	12	178 (89–355)	25	183 (114–295)
	Visit 19 (Y 7)	12	244 (109–548)	12	237 (106–533)	24	267 (151–473)
	Visit 20 (Y 8)	12	143 (66–309)	12	189 (88–409)	24	174 (101–300)
	Visit 21 (Y 9)	12	299 (137–650)	12	224 (103–486)	24	251 (145–436)
	Visit 22 (Y 10)	12	178 (82–388)	12	189 (87–411)	24	157 (91–273)
≥60	P.b. V48P7E1	4	173 (71–425)	3	573 (203–1616)	7	498 (253–982)
	Visit 18 (Y 6)	4	189 (52–688)	3	96 (22–427)	7	76 (29–202)
	Visit 19 (Y 7)	4	133 (26–677)	3	120 (18–789)	7	105 (31–360)
	Visit 20 (Y 8)	4	128 (26–620)	3	81 (13–504)	7	71 (21–234)
	Visit 21 (Y 9)	4	224 (52–965)	3	67 (12–362)	7	128 (42–385)
	Visit 22 (Y 10)	4	181 (35–928)	3	57 (9–377)	7	72 (21–248)

GMT, geometric mean titer; TBE, tick-borne encephalitis; PP, per-protocol; TBE_R, TBE_C and TBE_AC, rapid, conventional and accelerated conventional TBE vaccination schedules in the V48P7 study; P.b., baseline post-booster.